

JUL 25 2001

K003949

510(k) Summary

As Required by 21 section 807.92 (c)

- 1-Submitter Name:** A & A Medical, Inc.
2-Address: 9370 Industrial Trace
Alpharetta, GA 30004
3-Phone: (770) 343- 8400
4-Fax: (770) 343- 8985
5-Contact Person: Jihad Mansour
6-Date summary prepared: December 15th, 2000
7-Device Trade or Proprietary Name: Tacker
8-Device Common or usual name: Endoscopic stapler
9-Device Classification Name: Endoscope and/or accessories
10-Substantial Equivalency is claimed against the following device:
- Origin Tacker system

11-Description of the Device:

The device is to be used by physicians in hospitals

The Tacker is a device that consists of one disposable component and two permanently implantable components. The disposable component is a 45cm long stainless steel tube. The first permanently implantable component is a helical fastener. The second permanently implantable component is a PROLENE non-absorbable "O" suture.

The instrument is designed for introduction and use through an appropriately sized trocar sleeve or larger with the use of an appropriate seal.

12-Intended use of the device:

This device is indicated for use in endoscopic surgery procedures for urethropexy, including fixation of prostatic material, approximation of tissues in various surgical specialties, such as repair of hernias and bladder neck suspension.

13-Safety and Effectiveness of the device:

This device (**Tacker**) is safe and effective as the other predicate device cited above.
This is better expressed in the tabulated comparison (Paragraph 14 below)



JUL 25 2001

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850Mr. Jihad Mansour
Quality and Regulatory Manager
A & A Medical, Inc.
9370 Industrial Trace
ALPHARETTA GA 30004Re: K003949
Medical Tacker, Model #R65-933
Dated: May 8, 2001
Received: May 14, 2001
Regulatory Class: II
21 CFR §876.1500/ Procodes: 78 K0G and 79 GCJ

Dear Mr. Mansour:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure (s)

510(k) Number (if known): K003949

Device Name: TACKER

Indications For Use:

THIS DEVICE IS INDICATED FOR USE IN
ENDOSCOPIC SURGERY PROCEDURES FOR URETHROPEXY,
INCLUDING FIXATION OF PROSTATIC MATERIAL,
APPROXIMATION OF TISSUES IN VARIOUS SURGICAL
SPECIALTIES, SUCH AS REPAIR OF HERNIAS AND
BLADDER NECK SUSPENSION

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒
(Per 21 CFR 801.109)

OR

Over-The-Counter Use ☐

(Optional Format 1-2-96)

Nancy C. Bragdon
(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices

510(k) Number K003949